Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A decade of change

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Figure 1: Indexed number of active substances entering each phase of development from 2001 to 2009.
Figure 2: Probability of success to market from key milestones.
Figure 3: Changes in the percentage of lead projects in each development phase between 2001 and 2010 by asset origin.
Figure 4: R&D budgets in 2010 for top spenders.
Figure 5: Changes in therapeutic area focus from 2001 to 2010, for new drugs in all stages from Phase I trials to submission.


  1. Lamattina, J. The impact of mergers on pharmaceutical R&D. Nature Rev. Drug Discov. 10, 559 (2011).

    Article  CAS  Google Scholar 

  2. Slatko, J. The future belongs to biologics. Med Ad News 16, 34 (2010).Article

    Google Scholar 

  3. Arrowsmith, J. Trial watch: Phase II failures: 2008–2010. Nature Rev. Drug Discov. 10, 328–329 (2011).Article

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Arrowsmith, J. A decade of change. Nat Rev Drug Discov 11, 17–18 (2012).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research